H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Savara (SVRA) to $10 from $8 and keeps a Buy rating on the shares. The company resubmitted the application for Molbreevi with Fujifilm Diosynth as its drug substance manufacturer, the analyst tells investors in a research note. The firm believes Savara is increasingly well positioned ahead of a potential Molbreevi launch.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
- Savara resubmits Molbreevi BLA to the FDA
- Savara announces EPO intention to grant Molbreevi patent application
- Savara’s MOLBREEVI: A Promising Solution for aPAP with Blockbuster Potential
- Savara rumor highlighted in Betaville blog